China CAS:595-33-5 Manufacturer

Our growth depends to the superior products ,great talents and repeatedly strengthened technology forces for CAS:595-33-5, Our firm quickly grew in size and reputation because of its absolute dedication to superior quality manufacturing, substantial price of solutions and fantastic customer services.
CAS:595-33-5, Our company insists on the principle of "Quality First, Sustainable Development", and takes "Honest Business, Mutual Benefits" as our developable goal. All members sincerely thank all old and new customers' support. We'll keep working hard and offering you the highest-quality goods and service.

Hot Products

  • Nintedanib Esylate

    Nintedanib Esylate

    Nintedanib Esylate has in-house specification. DMF available.

    CAS:656247-18-6

  • Oseltamivir Phosphate

    Oseltamivir Phosphate

    Oseltamivir Phosphate has CP ,EP and USP specifications. DMF available.

    CAS:204255-11-8

  • Revefenacin

    Revefenacin

    Revefenacin has In-house specification. DMF approved.

    CAS:864750-70-9

  • Compound Mifepristone Tablets

    Compound Mifepristone Tablets

    Compound Mifepristone Tablets Specifications:Mifepristone 30mg Anorethidrane 5mg*2
    Indications:Abortion
  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • 4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic acid

    4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic acid

    4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic acid is an intermediate of Dutasteride.

    CAS:103335-55-3

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept